Speciality: Oncology
Description:
In this insightful panel discussion, renowned oncologists Dr. Tushar Patil, Dr. Varun Nagori, and Dr. Amol Dongre explore the evolving landscape of first-line maintenance therapy for metastatic urothelial carcinoma (UC). The conversation delves into key clinical trials, real-world applications, and the integration of novel therapies into standard practice. Experts weigh in on the latest evidence, patient selection strategies, and the role of immunotherapy in improving outcomes for advanced UC patients.
The discussion highlights how emerging data from trials like JAVELIN Bladder 100 are reshaping treatment paradigms. The panel examines the practical challenges of implementing maintenance therapy, including patient monitoring, toxicity management, and biomarker-driven decision-making. By connecting trial findings with day-to-day oncology practice, this session provides actionable insights for clinicians managing metastatic UC.
As the conversation concludes, the experts summarize essential takeaways for optimizing first-line maintenance therapy while emphasizing the need for further research. The panel also looks ahead at upcoming advancements in UC treatment, encouraging continuous learning and adaptation in oncology care. Stay tuned for more expert-led discussions on cutting-edge cancer therapies- this session is a must-watch for oncologists seeking evidence-based strategies.
See More Webinars @ Hidoc Webinars
1.
Datopotamab Deruxtecan Earns New Breast Cancer Indication
2.
Both DNA damage repair deficiency and non-Hodgkin lymphoma are the focus of LP-284.
3.
Clinical Evidence Shows Venetoclax Combo Is Safe and Effective in AML Patients 80 Years of Age and Up.
4.
The pancreatic ductal adenocarcinoma mRNA vaccine holds promise for preventing relapse.
5.
CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma
1.
Engineered Red Blood Cell Therapeutics: Emerging Applications
2.
A New Hope: Exploring Treatment Options for Waldenstrom's Macroglobulinemia
3.
AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined
4.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
5.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation